Articles related to Pulmonology
Sotrovimab No Longer Authorized to Treat COVID-19 in Areas with High BA.2 Frequency
The FDA has withdrawn its authorization for use of the monoclonal antibody sotrovimab in the treatment of COVID-19 in regions with a high frequency of the Omicron BA.2 subvariant. Data show that the authorized dose of the monoclonal antibody — 500 mg — is unlikely to be effective against the BA.2 COVID-19 subvariant.
Allergy & Immunology April 5th 2022
Lung Screening’s Benefits, Challenges
In March 2021, the US Preventive Services Task Force expanded the eligibility for lung cancer screening by setting the benchmark at a 20 pack-year smoking history for those ages 50 to 80 years who are current smokers or former smokers who have quit within the past 15 years. The new criteria will boost the number of eligible adults by 87% overall, according to a modeling analysis. It also could reduce lung cancer deaths by 13% versus 10% previously.
Internal Medicine March 15th 2022
Elderly Man Presents With Bradycardia and Chronic Kidney Dysfunction
An interesting case study in BRASH (bradycardia, renal failure, atrioventricular blockade, shock, and hyperkalemia) syndrome highlights Rare Disease Day, which took place on 2/28/22. After reviewing the patient’s history and symptoms, would you agree on the diagnosis?
Cardiology March 1st 2022
Risks of Mental Health Outcomes in People with COVID-19: Cohort Study
The British Medical Journal reports that people who survive COVID-19 are at increased risk of an array of mental health disorders, including anxiety, depression, and opioid use disorder, cognitive decline, sleep disorders, and more. The authors recommend close monitoring of patients following infection and up-prioritizing managing their mental health disorders.
Allergy & Immunology March 1st 2022
Lung Cancer: Five-Year Survival Outcomes from the PACIFIC Trial
This update on the PACIFIC trial comparing durvalumab with placebo in patients with unresectable, stage III non–small-cell lung cancer demonstrated robust and sustained OS and durable PFS benefit. The updated, exploratory analyses of survival, approximately 5 years after the last patient was randomly assigned demonstrate robust and sustained OS and durable PFS benefit with durvalumab after chemoradiotherapy. An estimated 42.9% of patients randomly assigned to durvalumab remain alive at 5 years and 33.1% of patients randomly assigned to durvalumab remain alive and free of disease progression. These results establish a new benchmark for standard of care in this setting.
Oncology, Medical February 23rd 2022
The Incidence of SARS-CoV-2 Reinfection in Persons with Naturally Acquired Immunity with and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine
This Annals of Internal Medicine study reports an 82% decreased risk for reinfection for those previously infected and then vaccinated, versus those previously infected but who remained unvaccinated. Reinfection in both groups was relatively rare.
Allergy & Immunology February 23rd 2022